- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marco Herold
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A generous vision for impactful medical research
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Philanthropy through the power of sisterhood
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Melanoma

Melanoma is an aggressive form of skin cancer. The disease can be effectively treated if detected early but is dangerous once it spreads throughout the body.
Australia has one of the highest incidence rates of melanoma in the world, with the disease being the third most diagnosed cancer in the country. More than 1400 Australians die from the disease each year. Our research aims to develop new strategies for treating advanced cases of melanoma.
Melanoma research at WEHI
Our researchers are:
- Investigating how specialised immune cells called natural killer cells prevent melanoma from spreading.
- Exploring whether natural killer cells could be harnessed to fight melanoma.
- Developing treatments that target the proteins keeping melanoma cells alive.
- Studying how melanomas evolve and develop resistance to therapies.
What is melanoma?
Melanoma is a type of skin cancer that arises in skin cells called melanocytes.
Melanocytes sit in the top layer of skin, called the epidermis. They produce a pigment which gives skin its colour and helps protect against ultraviolet (UV) damage. When melanocytes group together in clusters, they form a non-cancerous mole.
Occasionally melanocytes begin to grow abnormally and form a melanoma. Melanoma usually occurs on parts of the body that are exposed to the sun, but rare cases occur in body parts that receive less sun exposure, such as the inside of the mouth.
Melanoma is a rare type of skin cancer, but it is the most deadly. Melanoma is particularly dangerous because it can invade deeper layers of skin and spread to other parts of the body like the lung, liver and brain.
Excluding less deadly types of skin cancer, melanoma is the third most common cancer diagnosed in Australian men and women.
Symptoms of melanoma
The first sign of melanoma is usually a change in an existing mole, or the appearance of a new mole. Melanomas vary greatly in how they look, but many show features such as:
- Asymmetry
- Irregular shape or border
- Uneven colour
- Increased size
- Itching or bleeding
- Raised surface
As not all melanomas show these classic features, it is important that a doctor checks any moles that change in shape or grow over a period of more than one month. Suspicious moles should be removed and examined by a pathologist to look for signs of melanoma.
Risk factors for developing melanoma
Melanoma is caused by genetic changes in melanocytes. These genetic changes are caused by UV radiation from the sun or from other sources such as solariums.
Factors that increase the risk of developing melanoma include:
- Prolonged sun exposure, particularly during childhood.
- Having a large number of moles, especially those with irregular shape.
- Having fair or freckled skin, blue or green eyes and fair or red hair.
- Having a previous case of melanoma.
- Having a family history of skin cancer, especially melanoma.
How is melanoma treated?
If melanoma is detected early, it can usually be successfully removed by surgery. For this reason, survival from melanoma is relatively high, with 90 per cent of people alive five years after diagnosis.
Once melanoma has spread, however, the disease can be life-threatening.
Traditional chemotherapy drugs are generally not effective in treating melanoma, and until recently, there were few treatment options for advanced disease.
Several promising treatments have recently been developed for melanoma, including:
- Targeted therapies that block specific proteins that drive melanoma growth.
- Immunotherapies that activate the body’s own immune system to fight melanoma.
These new therapies have improved survival and reduced symptoms for many people diagnosed with advanced melanoma, however there are still many challenges.
Working towards improved outcomes
Drug resistance is a major problem for targeted therapies, with many people having a favourable initial response but then relapsing with resistant disease. Our researchers are using cutting-edge genome technology to investigate how melanomas evolve to become drug resistant. We are also developing new drugs targeting the pro-survival proteins that are often highly expressed in drug-resistant melanomas.
Our researchers are also exploring new forms of immunotherapy based on specialised immune cells called natural killer (NK) cells. NK cells patrol the body and kill damaged cells, including cancer cells and cells infected with viruses. Our researchers discovered that NK cells are essential to eliminate melanoma cells that have spread to the lungs. They are now investigating new treatments for melanoma that harness NK cells.
Support for people with melanoma
WEHI researchers are not able to provide specific medical advice to individuals. If you have melanoma or are supporting somebody with this disease, please contact the Cancer Council or consult your medical specialist.
Researchers:
Super Content:
Our bodies are constantly fighting off the development of cells that lead to tumours. Researchers have now discovered a protein ‘brake’ within Natural Killer cells that controls their ability to destroy their target tumour cells.
A new compound has been shown to block a protein essential for the growth of many cancers, including melanoma, blood, breast and lung cancers.
Researchers have discovered the mechanism that drives specialised immune cells that detect and kill cancer cells in the body, offering scientists a new way to develop potential drug targets and cancer treatments.
Computational biology has enabled our researchers to develop a new method to identify melanoma patients with improved rates of survival.